| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 302.1% | Wedbush | $27 → $23 | Maintains | Outperform |
| 08/16/2023 | 372.03% | Wedbush | → $27 | Reiterates | Outperform → Outperform |
| 08/11/2023 | 372.03% | Wedbush | → $27 | Reiterates | Outperform → Outperform |
| 06/30/2023 | 337.06% | JP Morgan | $24 → $25 | Maintains | Overweight |
| 06/28/2023 | 337.06% | Truist Securities | → $25 | Reiterates | Buy → Buy |
| 06/28/2023 | 389.51% | RBC Capital | → $28 | Reiterates | Outperform → Outperform |
| 06/27/2023 | 337.06% | Truist Securities | → $25 | Reiterates | Buy → Buy |
| 05/16/2023 | 319.58% | JP Morgan | $25 → $24 | Maintains | Overweight |
| 05/12/2023 | 372.03% | Wedbush | → $27 | Reiterates | Outperform → Outperform |
| 05/01/2023 | 337.06% | Truist Securities | → $25 | Initiates Coverage On | → Buy |
| 02/28/2023 | 337.06% | JP Morgan | $27 → $25 | Maintains | Overweight |
| 11/04/2022 | 406.99% | RBC Capital | $31 → $29 | Maintains | Outperform |
| 08/25/2022 | -12.59% | Goldman Sachs | → $5 | Downgrades | Neutral → Sell |
| 05/24/2022 | -12.59% | Goldman Sachs | $8 → $5 | Maintains | Neutral |
| 05/12/2022 | 39.86% | Goldman Sachs | $11 → $8 | Maintains | Neutral |
| 05/12/2022 | 424.48% | SVB Leerink | $34 → $30 | Maintains | Outperform |
| 04/13/2022 | 441.96% | RBC Capital | → $31 | Initiates Coverage On | → Outperform |
| 02/14/2022 | 459.44% | JP Morgan | $33 → $32 | Maintains | Overweight |
| 01/06/2022 | 476.92% | JP Morgan | $30 → $33 | Maintains | Overweight |
| 04/20/2021 | 494.41% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
| 04/20/2021 | 564.34% | Wedbush | → $38 | Initiates Coverage On | → Outperform |
| 04/20/2021 | 494.41% | JP Morgan | → $34 | Initiates Coverage On | → Overweight |
| 04/19/2021 | 441.96% | Goldman Sachs | → $31 | Initiates Coverage On | → Neutral |
What is the target price for Edgewise Therapeutics (EWTX)?
The latest price target for Edgewise Therapeutics (NASDAQ: EWTX) was reported by Wedbush on November 10, 2023. The analyst firm set a price target for $23.00 expecting EWTX to rise to within 12 months (a possible 302.10% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Edgewise Therapeutics (EWTX)?
The latest analyst rating for Edgewise Therapeutics (NASDAQ: EWTX) was provided by Wedbush, and Edgewise Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Edgewise Therapeutics (EWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewise Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewise Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Edgewise Therapeutics (EWTX) correct?
While ratings are subjective and will change, the latest Edgewise Therapeutics (EWTX) rating was a maintained with a price target of $27.00 to $23.00. The current price Edgewise Therapeutics (EWTX) is trading at is $5.72, which is out of the analyst's predicted range.